pycnogenol-endothelin-1

この研究の注釈：

Supplementation of 125mg pycnogenol daily for 12 weeks in type II diabetics currently on ACE inhibitor therapy showed benefits to blood pressure in 58.3% of subjects by halving their required dosage of ACE inhibitor. Other biomarkers, such as endothelin-1, glucose, and HbA1c all decreased relative to placebo.

A reduction in urinary albumin was noted after two months but this may have reached significance due to a spike in the placebo group, both groups normalized within three months of supplementation and there was no significant differences at this time.

Most effects required two months of supplementation to manifest, maintaining in potency for the third month and not occurring within the first.

研究の資金源に関する問題点：

Study funded by Horphag research, producers of pycnogenol supplements

この研究の注釈：

A dose-scaling open label study using four doses of pycnogenol (50mg, 100mg, 200mg, and 300mg) each for three sequential weeks noted a dose-dependent or time-dependent effect peaking after nine weeks (the 200mg dose) and maintaining for the remaining three weeks with 300mg pycnogenol. The parameter measured was blood glucose in type II diabetics, and the magnitude of reduction was 11-13%.

HbA1c also decreased from 8.02% down to 7.37%, this reached significance after nine weeks and endothelin-1 was similarly decreased (104+/-16pg/mL down to 91+/-15pg/mL) although reaching significance after six weeks; 300mg did not outperform 200mg on any parameter.

Insulin and its secretion appeared to be unaffected.

研究の資金源に関する問題点：

Funded by Horphag Research, a producer of pycnogenol